BioCentury

7:00 AM GMT, May 24, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

Northera droxidopa: Extension study data

Top-line data from the 3-month, open-label phase of the Study 303 extension study in 75 patients showed that Northera significantly decreased OHQ composite scores by a mean of 3.2 units

Read the full 306 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.